[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: INO-4800: INO-4800 contains the plasmid pGX9501; which encodes for the full length of the Spike glycoprotein of SARS-CoV-2. Two 1.0mg ID injections of INO-4800 followed immediately by Electroporation administered in separate limbs at Day 0 and Day 28 (\u00c2\u00b13 days)Control Intervention1: SSC-0001: Two ID injections of SSC-0001 (sterile saline sodium citrate buffer) followed immediately by Electroporation administered in separatelimbs at Day 0 and Day 28 (\u00c2\u00b13 days)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: INO-4800: INO-4800 contains the plasmid pGX9501; which encodes for the full length of the Spike glycoprotein of SARS-CoV-2. Two 1.0mg ID injections of INO-4800 followed immediately by Electroporation administered in separate limbs at Day 0 and Day 28 (\u00c2\u00b13 days)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: SSC-0001: Two ID injections of SSC-0001 (sterile saline sodium citrate buffer) followed immediately by Electroporation administered in separatelimbs at Day 0 and Day 28 (\u00c2\u00b13 days)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 653, "treatment_name": "Ino-4800", "treatment_type": "Dna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]